FP
RNAC icon

Flagship Pioneering’s Cartesian Therapeutics RNAC Stock Holding History

Flagship Pioneering’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27,562
Closed -$11.8M – 7
2017
Q1 		$11.8M Hold
27,562
– – 3.15% 5
2016
Q4 		$14.2M Sell
27,562
-27,500
-50% -$16.1M 4.61% 5
2016
Q3 		$23.5M Buy
+55,062
New +$21.5M 6.43% 5

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Flagship Pioneering's RNAC Position: Q2 2017 in Review

Flagship Pioneering sold out of Cartesian Therapeutics (RNAC) in Q2 2017, closing a stake of 27,562 shares — an estimated $11.8M sold.

Flagship Pioneering first reported a position in RNAC in Q3 2016 and held it in 3 quarters. The position peaked at $23.5M in Q3 2016. 48 funds tracked by Wall St. Rank hold RNAC as of Q2 2017.

  • Flagship Pioneering reported no remaining Cartesian Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Flagship Pioneering sold 27,562 Cartesian Therapeutics shares in Q2 2017, an estimated $11.8M.
  • Flagship Pioneering first reported a position in Cartesian Therapeutics in Q3 2016 and held it in 3 quarters.
  • Flagship Pioneering's Cartesian Therapeutics position peaked at $23.5M in Q3 2016.
  • 48 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2017.

Based on Flagship Pioneering's 13F filing for Q2 2017, filed 2 Aug 2017.